Asian Tech Press -- Yin Weidong, chairman and CEO of Sinovac Biotech Ltd (SVA: NASDAQ GS), said in a speech at the first International Forum on Vaccine Cooperation on August 5, that Sinovac will soon submit applications to national drug regulatory authorities in several countries for clinical studies and Emergency Use Authorization (EUA) of its COVID-19 vaccines against Gamma and Delta variants.
Yin also said that the company has sufficient production capacity to provide different types of its COVID-19 vaccine -- CoronaVac -- to everyone.
Sinovac CEO also revealed that the company has now completed a study on the third shot, or the booster dose of CoronaVac, which confirmed that the third dose is still as safe as the first and second ones, while the neutralizing antibody level can be increased significantly and quickly within one week.
Scientists from the Chinese Academy of Sciences (CAS) will reportedly soon publish their latest findings in Science, especially the good news about the vaccine's enhanced protection against COVID-19 variants after immunity is boosted.
The company said that real-world studies with the booster vaccine have been conducted in China, Turkey, Chile and other countries and results will be available soon.
Public information shows that last December, Sinovac Life Sciences Co., Ltd., Sinovac's Beijing-based R&D unit, isolated an infectious strain of the Delta variant, and in April isolated that of the Delta variant, and put into the research of changing strain of the inactivated COVID-19 vaccine.
Some epidemiologists pointed out that the work of strains change requires a judgment of epidemic strain trends before continuing. However, as long as the preliminary preparations are sufficient, the mainstream strain can be replaced at any time.
It is reported that, from the official findings, the COVID-19 outbreaks in Nanjing, Zhengzhou, and other regions of China are associated with the Delta variant.
He Qinghua, an official of China's National Health Commission (NHC), said at a press conference on Thursday on the State Council's joint COVID-19 prevention and control mechanism that the Delta variant did not lead to subversive changes in the biological characteristics of the novel coronavirus.
The Chinese official claimed that it is basically clear about the sources of infection and transmission routes, and that existing COVID-19 prevention and control measures are still effective against the Delta variant.
He also said that the current vaccines still have good preventive and protective effects, which can lower the risk of virus transmission in the population, reduce transmission from infected people, and effectively decrease the incidence of severe illness and death rate after infection.
Currently, the Delta variant is the predominant strain of COVID-19 around the world, which has been prevalent in more than 130 countries and regions. The World Health Organization announced on May 10 of this year that the Delta variant was included in the list of Variants of Concern (VOCs).
Amid outbreaks of COVID-19 in China, Chinese pharmaceutical companies and research institutions have been working hard to advance vaccine development.
In addition to Sinovac, the state-owned China National Pharmaceutical Group (Sinopharm), and Shenzhen Kangtai Biological Products Co., Ltd. (BioKangtai), have also carried out vaccine research and development against the Delta variant.
It is reported that China National Biotec Group (CNBG), a subsidiary of Sinopharm, is developing an inactivated vaccine against the Beta variant and it is currently in the animal testing stage. An inactivated vaccine against the Delta variant is also under development.
In other technical lines, CNBG is also working on the R&D of recombinant protein vaccine and mRNA vaccine for COVID-19 variants, sources familiar with the matter said.
"For an inactivated vaccine against the Delta variant, we recently filed a clinical study application," CNBG vice president Zhang Yuntao told the media on Thursday.
Also on Thursday, BioKangtai said in a public release that the company has made important progress in its vaccine development project for COVID-19 variants, and has successfully isolated several monoclonal strains of the Delta variant.
本文转载自Asian Tech Press, 原文标题为：Sinovac to file for EUA for its COVID-19 vaccine against Delta variant in countries